# SLQT earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/SLQT) · [Earnings tab](https://www.lopjlb.com/stock/SLQT?tab=earnings)

Updated: 2026-08-25T06:05:09

Quarters analyzed: 8

## Cross-quarter narrative

Across 8 calls for SLQT, management tone moved from +0.00 (2024 Q4) to +0.70 (2026 Q3). Latest guidance stance: maintained. Latest desk line: SLQT Q3: $431M rev (+6% YoY), $45M adj EBITDA (+18%), reaffirmed FY26 guide; Senior 8% growth, 26% EBITDA margin excl. $14M receivables adj; Healthcare Services 5% growth, IRA hit revenue but low EBITDA impact; SelectRx scaling, Olathe facility 30%+ efficiency; new SelectQuote Local franchise model;

## Latest CallCard · Q3

SLQT Q3: $431M rev (+6% YoY), $45M adj EBITDA (+18%), reaffirmed FY26 guide; Senior 8% growth, 26% EBITDA margin excl. $14M receivables adj; Healthcare Services 5% growth, IRA hit revenue but low EBITDA impact; SelectRx scaling, Olathe facility 30%+ efficiency; new SelectQuote Local franchise model;

**Guidance:** maintained — Reaffirmed fiscal 2026 outlook; not adjusting guidance despite $14M favorable receivables adjustment; FY27 guide expected after carrier planning cycles this summer.

**Tone:** mgmt 0.7 · Q&A pressure 0.4 · divergence 0.3

CEO and CFO emphasize strong results across segments, 4th consecutive year of 25%+ Senior EBITDA margins, reaffirmed FY26 outlook, excitement about FY27 cash flow compounding, and 'wildly dislocated valuation' narrative.

### Demand visibility

Strong demand in Senior (OEP) and Healthcare Services (SelectRx), but visibility mixed due to IRA and carrier approval rate dynamics.

Senior: 4% approved MA policy growth with materially higher approval rates vs prior years, possibly pulling forward volume from Q4. Healthcare Services: 11% membership growth (moderating), strong SelectRx demand. Life: Final Expense commissions up >8% YoY, Term Life competitive with media consumption shifts.

### Margins / costs

Senior 26% EBITDA margin excl. adjustment (4th straight year 25%+ full-year); Healthcare Services $5M adj EBITDA improving sequentially; Olathe facility driving 30%+ efficiency gains on <20% utilization.

Senior segment 26% EBITDA margin excluding $14M favorable receivables adjustment; 4 consecutive years of 25%+ full-year EBITDA margins. Healthcare Services impacted by IRA (low single-digit millions EBITDA impact) and carrier reimbursement changes. Olathe distribution facility (online Apr 2025) shipping <20% of prescriptions at 30%+ efficiency gains vs legacy sites; proprietary pharmacy management system in testing. Life Insurance $6M adj EBITDA.

### Capital allocation

Prioritizing cash flow generation and deleveraging; committed to NYSE listing maintenance; no buybacks or dividends mentioned.

Expect significant YoY operating cash flow improvement in FY26, building into FY27 with stated goal to delever balance sheet. Commissions receivable ~$1B asset. CEO: 'We will take all necessary action to maintain our listing on the New York Stock Exchange.'

### Milestones

- **SelectQuote Local franchise model** [new]: Fee-based arrangement offering marketing, tech, products, customer service platform to local providers; minimal capital investment; not meaningful near-term revenue but broadens reach.
- **Olathe, Kansas distribution facility** [on_track]: Online April 2025; <20% of prescriptions shipped, running 1 shift; 30%+ efficiency gains on those shipments; ample space to scale.
- **Proprietary pharmacy management system** [on_track]: In testing phase; upon completion will enable more SelectRx fulfillment through Olathe facility.
- **Senior segment 25%+ full-year EBITDA margins** [delivered]: Achieved for 4th consecutive year despite varying MA backdrops.
- **Commissions receivable ~$1B balance** [delivered]: 33% recapture rate over 2 disruptive MA seasons; LTV assumes 10 renewal years with 15% constraint.
- **SelectRx prescriptions shipped growth** [delivered]: 64% increase vs 2 years ago vs 55% member increase; operating leverage on fixed cost base.
- **Global revenue to CAC multiple 6.7x** [delivered]: Unique combination of Senior and Healthcare Services capabilities driving recurring cash flow streams.
- **15 Medicare seasons operated** [delivered]: Retention visibility through multiple cohorts; earliest cohorts still on books.

### Fears / risks

- **Regulatory**: Inflation Reduction Act setting maximum fair prices for 10 drugs drove notable sequential revenue drop in SelectRx; ongoing reimbursement pressure.
- **Market**: Medicare Advantage environment disruption over past 2 years pressures persistency and LTV assumptions; industry-wide enrollment disruption.
- **Operational**: Carrier approval rates materially higher than prior years; possible pull-forward from Q4 could weaken back-half trends.
- **Market**: Carrier marketing investment uncertainty for FY27; carriers go through annual planning cycles summer 2026.
- **Competitive**: Term Life remains competitive as consumers shift media consumption; Final Expense strength partially offset.
- **Financial**: NYSE listing maintenance risk with market cap under $200M; stock price pressure.
- **Accounting**: LTV assumptions (10 renewal years, 15% constraint) scrutinized since IPO; disruptive MA seasons test model.
- **Operational**: SEP period economics viability; quieter periods must work economically for direct-to-consumer model.

### Key quotes

> “We're pleased to report another quarter of strong financial results across each of our segments. We reaffirm our outlook for fiscal 2026 and continue to execute our goal to drive profitability and cash flow.” — Timothy Danker

> “Our Medicare Advantage commissions receivable balance at the end of fiscal third quarter totaled nearly $1 billion, which compares to our market cap of under $200 million today.”

> “Excluding the favorable adjustment, our consolidated EBITDA margin for fiscal 3Q would have been 7%, which is a strong result for an OEP quarter.”

> “We have fielded questions about the LTV assumptions in our commissions accounting going all the way back to our IPO, but I'd simply note that SelectQuote has just operated in 2 of the most disruptive Medicare Advantage environments on”

> “We're really able to make the quieter periods work economically and also enhanced by this unique asset we have called SelectRx and how our enterprise economics work even when the heartbeat might be a little slower during SEP.”

## Quarter one-liners

- **2026 Q3:** SLQT Q3: $431M rev (+6% YoY), $45M adj EBITDA (+18%), reaffirmed FY26 guide; Senior 8% growth, 26% EBITDA margin excl. $14M receivables adj; Healthcare Services 5% growth, IRA hit revenue but low EBITDA impact; SelectRx scaling, Olathe facility 30%+ efficiency; new SelectQuote Local franchise model;
- **2026 Q2:** SelectQuote posted a strong Q2 with 39% senior EBITDA margin and 26% health services revenue growth, but cut FY2026 guidance after a carrier’s marketing budget cut and PBM impact, while highlighting a new $415M credit facility and SelectRx expansion.
- **2026 Q1:** SelectQuote posted 13% revenue growth to $329M in Q1 2026, but faced a $21M senior EBITDA loss and a PBM reimbursement hit that pushes Healthcare Services to breakeven in Q2, while maintaining confidence in long‑term margins.
- **2025 Q4:** SelectQuote posted $1.5B revenue, 16% growth, record agent productivity and expanding healthcare services, while emphasizing cash‑flow generation and a focus on balance‑sheet strength for 2026.
- **2025 Q3:** SelectQuote Q3 FY25: $408M revenue (+8%), $38M EBITDA (9% margin). Senior 27% margins despite 26% smaller agent force. SelectRx at 106K members (+41%), $675M TTM revenue. Kansas facility opened April 7, near-term margin drag. DOJ complaint filed, company rejects allegations.
- **2025 Q2:** —
- **2025 Q1:** SelectQuote reports strong fiscal Q1 with 26% revenue growth, raised FY2025 outlook, record agent retention, successful $100M securitization, and 64% SelectRx membership growth.
- **2024 Q4:** —

## Theme arcs

- **Management tone** (improving): Δ mgmt=+0.70

## Fear persistence

- **medicare advantage plan benefit volatility** [resolved]: 2025 Q1
- **leverage profile limiting growth** [resolved]: 2025 Q1
- **seasonal healthcare services profitability pressure** [resolved]: 2025 Q1
- **dependence on carrier partnerships** [resolved]: 2025 Q1
- **agent capacity constraints in excess demand environment** [resolved]: 2025 Q1
- **future securitization execution risk** [resolved]: 2025 Q1
- **regulatory and forward-looking statement risks** [resolved]: 2025 Q1
- **legal/regulatory** [resolved]: 2025 Q3
- **market dynamics** [recurring]: 2025 Q3, 2025 Q3
- **execution** [recurring]: 2025 Q3, 2025 Q3

## Guidance path

2024 Q4:vague → 2025 Q1:raised → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:lowered → 2026 Q2:lowered → 2026 Q3:maintained

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/SLQT`